Anagenics Limited · ASX:AN1

Anagenics — Cellmid — Shareholder Meeting (November 2012)

18 slides from Anagenics's shareholder meeting presentation, Nov 23, 2012

  1. Slide 1: Annual General Meeting

    Slide 1: Annual General Meeting

    Annual General Meeting 23 November 2012 Maria Halasz CEO

  2. Slide 2: Forward-looking statements

    Slide 2: Forward-looking statements

    This presentation contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks that may cause the actual results, performance or achievements of Cellmid to be materially different from the statements in this presentation. Actual res

  3. Slide 3: Cellmid 2012

    Slide 3: Cellmid 2012

    Cellmid 2012 Significant near term revenue – OTC and diagnostics Strong product pipeline Track record in execution and delivery 3

  4. Slide 4: Significant near term revenue - OTC

    Slide 4: Significant near term revenue - OTC

    Significant near term revenue ‐ OTC • évolis hair growth products with TGA listed claims: • Promotes hair growth • Helps reduce hair loss and thinning • Helps restore the natural growth cycle of the hair by inhibiting FGF‐5 • Australian GMP manufactured • Launched in June 2012 • 700 chemists already

  5. Slide 5: First clinically validated hair growth product in 24 years

    Slide 5: First clinically validated hair growth product in 24 years

    First clinically validated hair growth product in 24 years Annual sales: Monoxidil $300M* Finasteride (Propecia) $1,097.6M* *Newport Horizon 5

  6. Slide 6: évolis vs minoxidil

    Slide 6: évolis vs minoxidil

    évolis® vs minoxidil évolis Minoxidil No reported side effects, very safe due to clear Poor side effect profile, including lethargy and mode of action depression with long term use No initial shedding Initial shedding often occurs, benefits take 3‐4 months to start Newly grown hair continues to grow

  7. Slide 7: Clinical study results

    Slide 7: Clinical study results

    Clinical study results Quantitative assessment • Rate of hair growth increased by 21% • Hair loss reduced by 35% Qualitative assessment • 74% found the treatment beneficial for hair growth 7

  8. Slide 8: Distribution

    Slide 8: Distribution

    Distribution 700 pharmacies Australian pharmacy by EOY 2012 sales 25% of pharmacies (1,300) by EOY 2013 Direct sales force Australian (commissioned agents) direct sales to Targeting 210 salons Advangen hairdressers by EOY 2013 International TVSN in Australia Electronic media and internet sales Group

  9. Slide 9: Strong product pipeline based on powerful patent position

    Slide 9: Strong product pipeline based on powerful patent position

    Strong product pipeline based on powerful patent position PRECLINICAL CLINICAL MARKET évolis® hair growth products MK‐ELISA (research market) MK metastatic colorectal diagnostic MK hepatocellular carcinoma diagnostic MK antibodies for inflammation and cancer MK for heart attack 9

  10. Slide 10: Diagnostics pipeline

    Slide 10: Diagnostics pipeline

    Diagnostics pipeline • License 1: Quest (Celera) lung cancer screening test • Product expected on market in mid 2013 • Milestone payment and royalties due on and after launch • License 2: Pacific Edge Diagnostics bladder cancer test • Product expected on market in 2013 • Milestone payment and royalt

  11. Slide 11: Therapeutics pipeline

    Slide 11: Therapeutics pipeline

    Therapeutics pipeline Animal studies Disease reduced by MK treatment? Preclinical DISEASE Reduced Clinical indication disease in RNAi mAbs and/or MK Inhibitors validation MK‐/‐? YES Osteosarcoma Cancer YES (multiple YES 50% Glioma/glioblastoma cancers) Metastasising carcinomas Surgical Abdominal sur

  12. Slide 12: Track record in execution and delivery

    Slide 12: Track record in execution and delivery

    Track record in execution and delivery Dr David King Graeme Kaufman Martin Rogers Maria Halasz 12

  13. Slide 13: 2012: Significant milestones - Funding

    Slide 13: 2012: Significant milestones - Funding

    2012: Significant milestones Funding • Nov 2011 Rights Issue and Placement of Shortfall (1.4M) • Feb 2012 La Jolla Funding Agreement Termination • April 2012 Cellmid Completes $1.5M Placement • Oct 2012 $748K R&D Tax Credit Received • Oct 2012 $545K Options Rights Issue Completed 13

  14. Slide 14: 2012: Significant milestones - Business

    Slide 14: 2012: Significant milestones - Business

    2012: Significant milestones Business • Dec 2011 Completed Midkine Study for Normal Reference Range • Feb 2012 TGA Registration and Launch of Cellmid's évolis Products • Mar 2012 Annual Report on Celera (Quest) License • Mar 2012 Media Launch of évolis Hair Products • April 2012 Commercial website l

  15. Slide 15: 2012: Significant milestones - Patent and Board

    Slide 15: 2012: Significant milestones - Patent and Board

    2012: Significant milestones Patent • April 2012 USA Antibody Patent for Adhesion Allowed • May 2012 USA Treg Antibody Patent Allowed • July 2012 USA Midkine Ischemia Patent Allowed Board • Aug 2012 Appointment of Graeme Kaufman • Sept 2012 Appointment of Martin Rogers 15

  16. Slide 16: 2013 Business outlook

    Slide 16: 2013 Business outlook

    2013 Business outlook Advangen • Growing distribution and sales for évolis in Australia and overseas • Increasing brand awareness of évolis • Building distribution for Advangen range (hairdressing salons) Therapeutic programs • Preclinical efficacy studies progressed and lead indication selected for

  17. Slide 17: Cellmid 2013

    Slide 17: Cellmid 2013

    Cellmid 2013 Opportunity to increase revenue from multiple channels Convert patent portfolio into products Increase market recognition 17

  18. Slide 18: Thank you

    Slide 18: Thank you

    Thank you www.cellmid.com.au Maria Halasz CEO (612) 9299 0311 halasz@cellmid com.au 18

Source: Internet Archive copy of anagenics.com

More decks from Anagenics Limited

All 38 Anagenics decks